Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran.
Metabolism. 2010 May;59(5):742-7. doi: 10.1016/j.metabol.2009.09.019. Epub 2009 Nov 18.
Osteoprotegerin (OPG) is an inhibitor of bone resorption. Circulating levels of OPG seem to be elevated in patients with cardiovascular disorders and diabetes. The relationship between OPG and the metabolic syndrome has never been studied in postmenopausal women. In a population-based study, 382 Iranian postmenopausal women were randomly selected. Cardiovascular risk factors, high-sensitivity C-reactive protein, and OPG were measured. The diabetes classification and the metabolic syndrome definition were based on the criteria of the American Diabetes Association and the National Cholesterol Education Program-Adult Treatment Panel III, respectively. The mean serum OPG level was higher in those with type 2 diabetes mellitus than those without diabetes (4.33 +/- 1.70 vs 3.84 +/- 1.76 pmol/L, P = .016). In multiple logistic regression analysis, type 2 diabetes mellitus showed a significant association with serum OPG levels when adjustments were made for age, high-sensitivity C-reactive protein, and cardiovascular risk factors (odds ratio = 2.21; confidence interval, 1.34-3.66; P = .002). No significant difference was found between the mean serum OPG levels of those with the metabolic syndrome and those without the metabolic syndrome. Mean OPG levels did not differ significantly between subjects with and without hypertension, dyslipidemia, glucose intolerance, or abdominal obesity according to the National Cholesterol Education Program-Adult Treatment Panel III criteria. In conclusion, circulating OPG levels are significantly associated with diabetes, independent of cardiovascular risk factors in postmenopausal women. However, OPG levels have no correlation with the metabolic syndrome or its components. Further studies are warranted to determine the pathophysiologic origin of elevated OPG in type 2 diabetes mellitus.
骨保护素（OPG）是骨吸收的抑制剂。循环中的 OPG 水平似乎在心血管疾病和糖尿病患者中升高。OPG 与代谢综合征之间的关系在绝经后妇女中从未被研究过。在一项基于人群的研究中，随机选择了 382 名伊朗绝经后妇女。测量了心血管危险因素、高敏 C 反应蛋白和 OPG。糖尿病的分类和代谢综合征的定义分别基于美国糖尿病协会和国家胆固醇教育计划-成人治疗小组 III 的标准。与无糖尿病的患者相比，2 型糖尿病患者的平均血清 OPG 水平更高（4.33 +/- 1.70 对 3.84 +/- 1.76 pmol/L，P =.016）。在多因素逻辑回归分析中，当调整年龄、高敏 C 反应蛋白和心血管危险因素后，2 型糖尿病与血清 OPG 水平呈显著相关（比值比=2.21；95%置信区间，1.34-3.66；P =.002）。代谢综合征患者和无代谢综合征患者的平均血清 OPG 水平无显著差异。根据国家胆固醇教育计划-成人治疗小组 III 的标准，高血压、血脂异常、葡萄糖耐量异常或腹部肥胖患者的平均 OPG 水平在有和无这些异常的患者之间无显著差异。结论：在绝经后妇女中，循环 OPG 水平与糖尿病显著相关，独立于心血管危险因素。然而，OPG 水平与代谢综合征或其成分无关。需要进一步的研究来确定 2 型糖尿病中 OPG 升高的病理生理起源。
